{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-041619","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.676512+00:00","generated_at":"2026-06-04T02:27:36.812062+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Candel reports CAN-2409 phase 2 interim data: median OS 28.8 vs 12.5 months in pancreatic cancer","bullets":["Estimated median overall survival 28.8 months for CAN-2409 group vs 12.5 months for control in borderline resectable PDAC.","24-month survival rate 71.4% for CAN-2409 vs 16.7% control; 36-month rate 47.6% vs 16.7%.","4 of 7 CAN-2409 patients alive at data cut-off (2 >50 months); only 1 of 6 control alive.","Immune activation confirmed: dense CD8+ TILs, dendritic cells, B cells in tumor; increased granzymes and IFN-γ in blood.","No dose-limiting toxicities or pancreatitis; FDA Fast Track Designation granted in December 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-041619","json":"https://secwatch.observer/filing/0000950170-24-041619.json","markdown":"https://secwatch.observer/filing/0000950170-24-041619.md","text":"https://secwatch.observer/filing/0000950170-24-041619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024041619/0000950170-24-041619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024041619/cadl-20240404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:27:36.812062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}